Amylyx spent two years shrinking itself back into a clinical-stage company, and the second quarter showed the operating shape of that smaller business one last time before the most consequential readout of its history. With the last participant now through the 16-week double-blind period of the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, the company is sitting roughly three weeks from a topline announcement that will either ratify the post-RELYVRIO reset or force another one. The financial story this quarter was unremarkable on purpose. Research and development fell to $23.8 million, down from $27.2 million a year earlier, on the wind-down of the discontinued AMX0035-PSP program. Selling, general and administrative rose to $21.9 million from $15.6 million, almost entirely legal expense tied to the just-settled securities class action and the early build of an avexitide launch infrastructure. Net loss came in at $43.4 million, or $0.39 per basic and diluted share, against a year-ago loss of $41.4 million, or $0.46 per share. Cash, cash equivalents, and marketable securities ended June at $250.8 million, down from $279.8 million at the end of the first quarter, with management's stated runway extending into 2028.
The price action tells the rest. The stock traded around $23.35 in the days after earnings, near its 52-week high of $24.60 set on August 7 and a 1-year return of roughly 181% off the August 2025 low of $7.63. The market is paying for the upcoming readout, not the quarter - total operating expenses of $45.7 million against zero product revenue, with no product approved anywhere, would otherwise anchor a small-cap biotech near cash, not at roughly ten times cash.
The LUCIDITY readout is the single event that matters between now and the next 10-Q, and the company's own framing leaves no ambiguity. The trial was designed with an FDA-agreed primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16, against placebo, in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Five prior trials, including a Phase 2 PREVENT crossover (n=18) and a Phase 2b investigator-initiated crossover (n=16), have shown consistent effects in that composite; the Phase 2b's 90 mg once-daily arm - the dose LUCIDITY uses - produced a 53% reduction in Level 2 events (p=0.004) and a 66% reduction in Level 3 events (p=0.0003) in an exploratory analysis, with no reported serious adverse events. If LUCIDITY lands in the same direction and magnitude, the company has said a 2027 commercial launch follows. If it does not, the cash runway buys management time to either pursue an alternative path for avexitide (congenital hyperinsulinism, where the molecule also has Breakthrough designation) or re-platform the rest of the pipeline. The thesis is binary and dated; that is what the stock is priced for.